Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor

GlobeNewswire

REDWOOD CITY, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the first patient was dosed in its first-in-human clinical trial evaluating RMC-5127, a RAS(ON) G12V-selective inhibitor.

The first-in-human trial, RMC-5127-001 [NCT07349537], is an open-label trial evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of RMC-5127 as both a monotherapy and in combination settings. The trial will enroll patients with RAS G12V–mutated solid tumors, including pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), and non–small cell lung cancer (NSCLC), who have progressed on or are intolerant to prior standard therapies, including targeted treatments.

“By bringing RMC-5127 to the clinic, we are building on our well-validated RAS(ON) inhibitor approach and extending it to RAS G12V, the second most common RAS mutation driving human cancers, where there are no approved targeted treatment options,” said Alan Sandler, M.D., chief development officer of Revolution Medicines. “As our fifth disclosed mutant-selective RAS(ON) inhibitor and fourth clinical-stage program, RMC-5127 broadens the RAS variant coverage of our growing portfolio and opens a suite of development opportunities aimed at improving outcomes for patients with RAS-driven cancers.”

RMC-5127 is an innovative inhibitor that binds to cyclophilin A, creating a complex that selectively recognizes and inhibits the oncogenic RAS(ON) form of the RAS G12V variant. RAS G12V is the second most common driver of RAS-addicted human cancers with approximately 48,000 patients diagnosed in the U.S.1 each year, predominantly among patients with PDAC, CRC, or NSCLC.

About Revolution Medicines, Inc. Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered "forward-looking statements," including without limitation statements regarding progression of clinical studies and findings from these studies, including the safety, tolerability and antitumor activity of the company’s candidates being studied and the durability of these results; dosing and enrollment in the company’s clinical trials; the potential impact of RMC-5127 for patients with KRAS G12V mutations; and the ability of the company to transform outcomes for patients with RAS-driven cancers. Forward-looking statements are typically, but not always, identified by the use of words such as "may," "will," "would," "believe," "intend," "plan," "anticipate," "estimate," "expect," and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause the company’s development programs, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including the company’s programs’ current stage of development, the process of designing and conducting preclinical and clinical trials, risks that the results of prior clinical trials may not be predictive of future clinical trials, clinical efficacy, or other future results, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, the company’s ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of the company’s capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape, and the effects on the company’s business of the global events, such as international conflicts or global pandemics. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Revolution Medicines in general, see Revolution Medicines’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 5, 2025, and its future periodic reports to be filed with the SEC. Except as required by law, Revolution Medicines undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

Revolution Medicines Media & Investor Contact:

media@revmed.com

investors@revmed.com

1 Estimated using tumor mutation frequencies from Foundation Medicine Insights March 2022 and scaled to estimated patient numbers using cancer incidence from ACS Cancer Facts and Figures 2023

Risk Warnings and Disclaimers

You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.

Add to Favorites

Revolution Medicines on Pace for Largest Percent Decrease Since October 2023 — Data Talk

Dow Jones Newswires

Revolution Medicines

-1.22%

Revolution Medicines, Inc. Warrant

-3.16%

Revolution Medicines, Inc. (RVMD) is currently at $97.66, down $19.97 or 16.98%

Would be lowest close since Jan. 6, 2026, when it closed at $79.85
On pace for largest percent decrease since Oct. 23, 2023, when it fell 34.38%
Currently down two consecutive days; down 17.8% over this period
Worst two day stretch since the two days ending Oct. 24, 2023, when it fell 24.85%
Up 22.61% month-to-date; on pace for best month since Nov. 2025, when it rose 32.15%
Up 22.61% year-to-date
Down 20.78% from its all-time closing high of $123.27 on Jan. 15, 2026
Up 139.77% from 52 weeks ago (Jan. 27, 2025), when it closed at $40.73
Down 20.78% from its 52-week closing high of $123.27 on Jan. 15, 2026
Up 213.72% from its 52-week closing low of $31.13 on April 8, 2025
Traded as low as $92.50; lowest intraday level since Jan. 7, 2026, when it hit $79.94
Down 21.36% at today's intraday low; largest intraday percent decrease since Oct. 23, 2023, when it fell as much as 44.8%

All data as of 2:11:13 PM ET

Source: Dow Jones Market Data, FactSet

Risk Warnings and Disclaimers

Add to Favorites

Intel, Oracle among market cap stock movers on Monday

Investing.com

Firefly Aerospace Inc.

+9.62%

Rich Sparkle Holdings Limited Ordinary Shares

-1.42%

Monday’s market has seen swings in various stocks based on news and other factors. Today, stocks like Oracle and Cisco are rallying, while stocks like Intel are falling. Below are highlights of some of the biggest stock movers, from mega-caps to small caps.

Mega-Cap Movers (Market Cap:$200B+)

Intel Corp (INTC) -5.16%
Oracle Corp (ORCL) +4.11%
Cisco Sys Inc (CSCO); Cisco launches new partner program to boost AI readiness +3.17%
Lam Research Corp (LRCX) +3.05%
Apple Computer Inc (AAPL) +2.9%
Avago Technologies (AVGO) +2.62%
Tesla Motors (TSLA) -2.36%
Adv Micro Device ( -2.53%
Micron Tech (MU) -2.13%
Google Inc (GOOGL); OpenAI Seeks Premium Prices in Early Ads Push - The Information +2.13%

Large-Cap Stock Movers (Market Cap:$10B-$200B)

Revolution Medicines Inc (RVMD); Revolution Medicines stock falls after Merck reportedly ends acquisition pursuit -16.92%
Cloudflare Inc (NET) +10.79%
Zoom Video Communications (ZM) +9.65%
Booz Allen Hamilton Holding Corp (BAH) -11.03%
CoreWeave (CRWV); DA Davidson upgrades CoreWeave stock to Buy on strengthening compute demand +9.35%
Trade Desk Inc (TTD); The Trade Desk appoints Tahnil Davis as interim CFO -8.43%
Fortress Value Acquisition Corp (MP) -8.13%
Vector Acquisition (RKLB) -6.83%
New Providence Acquisition Corp N (ASTS) -5.94%
Arista Networks (ANET) +5.9%

Mid-Cap Stock Movers (Market Cap:$2B-$10B)

Evolution Metals Tech (EMAT) -22.43%
Sustainable Opportunities Acqui (TMC) -18.45%
Corvus Pharmaceuticals Inc (CRVS) -14.22%
Inflection Point Acquisition II (USAR); USA Rare Earth secures $1.6 billion in proposed federal funding +14.21%
Redwire (RDW) -12.18%
Fly Leasing Ltd (FLY) -12.12%
DigitalOcean Holdings (DOCN) +12.23%
Pattern Group Inc (PTRN) +12.26%
Geo Group Inc (GEO) -11.7%
CF Acquisition Corp VI (RUMBW) -10.0%

Small-Cap Stock Movers (Market Cap:$300M-$2B)

Lands End I (LE) +39.72%
NovaBay Pharmaceuticals Inc (NBY) -32.06%
Rich Sparkle Holdings (ANPA) +24.46%
Anbio Biotechnology (NNNN) -23.56%
Ramaco Resources Inc (METC) -19.73%
Greenwich Lifesciences Inc (GLSI) +17.59%
CF Acquisition V (SATL); Satellogic raises $35 million in registered direct offering -15.71%
LightPath Technol (LPTH) -16.6%
Velo3D (VELO) -14.72%

For real-time, market-moving news, join Investing Pro.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Risk Warnings and Disclaimers

Add to Favorites

Revolution Medicines Down Over 17%, on Pace for Largest Percent Decrease Since October 2023 — Data Talk

Dow Jones Newswires

Revolution Medicines

-1.22%

Revolution Medicines, Inc. Warrant

-3.16%

Revolution Medicines, Inc. (RVMD) is currently at $97.12, down $20.52 or 17.44%

Would be lowest close since Jan. 6, 2026, when it closed at $79.85
On pace for largest percent decrease since Oct. 23, 2023, when it fell 34.38%
Currently down two consecutive days; down 18.26% over this period
Worst two day stretch since the two days ending Oct. 24, 2023, when it fell 24.85%
Up 21.93% month-to-date; on pace for best month since Nov. 2025, when it rose 32.15%
Up 21.93% year-to-date
Down 21.22% from its all-time closing high of $123.27 on Jan. 15, 2026
Up 138.44% from 52 weeks ago (Jan. 27, 2025), when it closed at $40.73
Down 21.22% from its 52-week closing high of $123.27 on Jan. 15, 2026
Up 211.97% from its 52-week closing low of $31.13 on April 8, 2025
Traded as low as $92.50; lowest intraday level since Jan. 7, 2026, when it hit $79.94
Down 21.36% at today's intraday low; largest intraday percent decrease since Oct. 23, 2023, when it fell as much as 44.8%

All data as of 11:10:35 AM ET

Source: Dow Jones Market Data, FactSet

Risk Warnings and Disclaimers

Add to Favorites

Intel and AMD among market cap stock movers on Monday

Investing.com

Oracle

-3.37%

Firefly Aerospace Inc.

Monday’s market has seen swings in various stocks based on news and other factors. Today, stocks like Intel (INTC) and Advanced Micro Devices ( are experiencing declines, while Cisco Systems (CSCO) and Oracle (ORCL) are seeing gains. Below are highlights of some of the biggest stock movers, from mega-caps to small caps.

Mega-Cap Movers (Market Cap:$200 billion USD or higher)

Intel Corp (INTC) -5.97%
Adv Micro Device (AMD) -3.4%
Cisco Sys Inc (CSCO); Cisco launches new partner program to boost AI readiness +2.29%
Apple Computer Inc (AAPL) +2.46%
Oracle Corp (ORCL) +3.05%
Tesla Motors (TSLA) -2.55%

Large-Cap Stock Movers (Market Cap:$10-$200 billion USD)

Revolution Medicines Inc (RVMD); Revolution Medicines stock falls after Merck reportedly ends acquisition pursuit -18.17%
CoreWeave (CRWV); DA Davidson upgrades CoreWeave stock to Buy on strengthening compute demand +12.93%
Cloudflare Inc (NET) +9.67%
Applied Blockchain (APLD) +6.17%
Hecla Mining Comp (HL); Hecla Mining achieves top end of silver and gold production guidance +5.23%
AngloGold Ashanti Ltd (AU) +5.19%
Regencell Bioscience Holdings (RGC) -7.26%
Fortress Value Acquisition Corp (MP) -7.8%
Generac Holdings (GNRC) -4.92%
Tempus AI (TEM) +5.77%

Mid-Cap Stock Movers (Market Cap:$2-$10 billion USD)

Inflection Point Acquisition II (USAR); USA Rare Earth secures $1.6 billion in proposed federal funding +8.82%
Sarepta (SRPT); Sarepta’s ELEVIDYS shows durable benefits in Duchenne patients +11.88%
DigitalOcean Holdings (DOCN) +9.14%
Mudrick Capital A (HYMC) +7.54%
Puyi ADR (MAAS) +7.94%
Sustainable Opportunities Acqui (TMC) -16.26%
Evolution Metals Tech (EMAT) -16.4%
Sizzle Acquisition (CRML) -8.92%
Bellring Brands LLC (BRBR) -7.94%
Fly Leasing Ltd (FLY) -9.73%

Small-Cap Stock Movers (Market Cap:$300 million - $2 billion USD)

Lands End I (LE) +35.02%
HUYA Inc ( +16.32%
Rich Sparkle Holdings (ANPA) +13.71%
InMode Ltd (INMD) +12.04%
NovaBay Pharmaceuticals Inc (NBY) -30.01%
CF Acquisition V (SATL); Satellogic raises $35 million in registered direct offering -16.93%
TCP Capital Corp (TCPC) -13.82%
Velo3D (VELO) -13.48%
Roth CH Acquisition V (NUAI) -7.75%
Bloomin Brands Inc (BLMN) -9.27%

For real-time, market-moving news, join Investing Pro.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Risk Warnings and Disclaimers

Add to Favorites

Revolution Medicines stock falls after Merck reportedly ends acquisition pursuit

Investing.com

Advanced Micro Devices

Investing.com -- Merck & Company Inc (NYSE:MRK) has ceased discussions to acquire biotechnology firm Revolution Medicines Inc (NASDAQ:RVMD), following a failure to reach an agreement on the company’s valuation. According to the Wall Street Journal, citing people familiar with the matter, the drug giant had been exploring a deal that could have valued the cancer-focused biotech at approximately $30 billion.

The collapse of the talks sent Revolution Medicines’ shares tumbling 20.9% in premarket trading on Monday. This retreat follows a period of intense speculation that had pushed the company’s market capitalization from $16 billion to more than $22 billion earlier this month.

The impasse reportedly centered on the purchase price, as Merck maintains a disciplined approach to its aggressive oncology acquisition strategy. Regarding the company’s financial flexibility, Merck Chief Executive Rob Davis stated at a recent conference, “We are not limited from a balance sheet,” but that the company is focused on deals for up to $15 billion.

Revolution Medicines is currently developing a pipeline of experimental drugs designed to inhibit RAS, a molecular driver found in many difficult-to-treat cancers. The company’s lead assets are being tested against lung, pancreatic, and colorectal tumors, with key clinical data expected in the first half of this year.

Earlier reports had also linked AbbVie to a potential bid for the biotech, though those rumors were eventually dismissed.

Despite the current breakdown in negotiations, observers note that a deal could still materialize if clinical results prove favorable or if a new suitor emerges. For now, Merck remains focused on its existing portfolio as it prepares for the upcoming loss of exclusivity for its top-selling drug, Keytruda.

Risk Warnings and Disclaimers

Add to Favorites

Baker Hughes, Allied Gold and Newmont rise premarket; American Airlines falls

Investing.com

Investing.com -- U.S. stock futures slipped marginally lower Monday at the start of a week that includes a Federal Reserve meeting as well as earnings from several tech giants.

Here are some of the biggest premarket U.S. stock movers today:

Allied Gold (NYSE:AAUC) stock gained 3% after Zijin Gold International (HK:2259) agreed to acquire the Canadian headquartered gold producer in an all-cash transaction valued at approximately C$5.5 billion.
USA Rare Earth (NASDAQ:USAR) stock soared 22% after reports that the Trump administration was taking a 10% stake in the miner as part of a $1.6 billion debt-and-equity investment package.
Gold miners Newmont (NYSE:NEM) and Barrick Mining (NYSE:B) both climbed sharply as bullion prices surged to a record high of $5,100 an ounce, extending a historic rally driven by safe-haven demand amid geopolitical uncertainties and market volatility.
Shares of American Airlines (NASDAQ:AAL), Delta Air Lines (NYSE:DAL) and United Airlines (NASDAQ:UAL) all fell by more than 1% on worries over possible flight delays and cancellations due to a heavy winter storm blanketing many American states.
Baker Hughes (NASDAQ:BKR) stock rose 2.2% after the energy services company reported an 11% rise in fourth quarter adjusted profit as demand for its gas technology equipment and services more than offset weakness in its oilfield services and equipment business.
Meta Platforms (NASDAQ:META) stock rose 0.6% after Redburn upgraded its stance on the Facebook owner to “buy” from “neutral”, saying the tech giant not only has the best ‘demand machine’ in the world, efficiently matching demand to supply, but is also best positioned to capitalise on two large AI opportunities.
Leidos (NYSE:LDOS) stock rose 0.7% after the defense contractor said it would buy power design firm ENTRUST Solutions Group from private equity firm Kohlberg for about $2.4 billion to bolster its engineering offerings for utilities.
Revolution Medicines (NASDAQ:RVMD) stock slumped 21% after the Wall Street Journal reported that Merck ended talks to acquire the biotech firm, citing people familiar with the matter.
Skywater Technology (NASDAQ:SKYT) stock gained 7.7%, with IonQ to acquire the company for $35.00 per share in a cash-and-stock transaction, implying a total equity value of approximately $1.8 billion.